| Aeterna Zentaris is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. Co.'s primary product, macimorelin, is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency. Macimorelin is marketed in the U.S. under the tradename Macrilen through a license agreement with Novo Nordisk. We show 4 historical shares outstanding datapoints in our AEZS shares outstanding history coverage, used to compute AEZS market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AEZS market cap history over the course of time is important for investors
interested in comparing AEZS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AEZS versus a peer is one thing; comparing
AEZS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AEZS can fluctuate over the course of history.
With this page we aim to empower investors researching AEZS by allowing them to research the AEZS market cap history.